Transteritin amyloid cardiomyopathy: a difficult patient for an internist
https://doi.org/10.21886/2712-8156-2024-5-4-111-118
Abstract
To enhance the clinical awareness and vigilance of healthcare professionals, such as therapists, cardiologists and neurologists, in the detection of ATTR amyloidosis among patients suffering from multi-organ damage, particularly in cases where heart failure with a preserved ejection fraction is progressing and resistant to standard treatment
About the Authors
N. V. Khailo
Rostov State Medical University
Russian Federation
Russian Federation
Natalya V. Khailo, Cand. Sci. (Med.), Associate Professor of the Department of Internal Diseases No. 1
Rostov-on-Don
E. V. Belovolova
Rostov State Medical University
Russian Federation
Russian Federation
Ekaterina V. Belovolova, Cand. Sci. (Med.), Associate Professor of the Department of Internal Diseases No. 1
Rostov-on-Don
O. V. Tseluiko
Rostov State Medical University
Russian Federation
Russian Federation
Oleg V. Tseluiko, assistant of the Department of Internal Diseases No. 1
Rostov-on-Don
D. A. Kalmykova
Rostov State Medical University
Russian Federation
Russian Federation
Daria A. Kalmykova, student of the 6th year of education
Rostov-on-Don
L. V. Morozova
Rostov State Medical University
Russian Federation
Russian Federation
Lyubov V. Morozova, student of the 6th year of education
Rostov-on-Don
References
1. Rameev V.V., Myasnikov R.P., Vinogradov P.P., Kozlovskaya L.V., Moiseev S.V., Fomicheva E.I., et al. Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage. Rational Pharmacotherapy in Cardiology. 2019;15(3):349-358. (In Russ.) DOI: 10.20996/1819-6446-2019-15-3-349-358
2. Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(9):1677-1696. DOI: 10.1002/ejhf.2589
3. Imdad U. Amyloidosis of the Heart: A Comprehensive Review. Cureus. 2023;15(2):e35264. DOI: 10.7759/cureus.35264
4. Tereshchenko S.N., Zhirov I.V., Moiseeva O.M., Adasheva T.V., Ansheles A.A., Barbarash O.L., et al. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii arkhiv. 2022;94(4):584-595. (In Russ.) DOI: 10.26442/00403660.2022.04.201465
5. Antropova O.N., Osipova I.V., Vishnyakova Т.S., Borisova L.V. Clinical case of amyloidosis of heart. Bulletin of Medical Science. 2021;3(23): 44–49. (In Russ.) DOI: 10.31684/25418475_2021_3_44
6. Reznik E.V., Nguyen T.L., Borisovskaya S.V., Brylev L.V., Zhelnin A.V., Seksyaev N.E. A Clinical Case of the Hereditary Transthyretin Amyloidosis. The Russian Archives of Internal Medicine. 2021;11(3):229-240. (In Russ.) DOI: 10.20514/2226-6704-2021-11-3-229-240
7. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7-e22. Erratum in: Circulation. 2021;144(1):e10. Erratum in: Circulation. 2021;144(1):e11. DOI: 10.1161/CIR.0000000000000792
8. Reznik E.V., Nguyen T.L., Stepanova E.A., Ustyuzhanin D.V., Nikitin I.G. Cardiac Amyloidosis: Internist and Cardiologist Insight. The Russian Archives of Internal Medicine. 2020;10(6):430-457. (In Russ.) DOI: 10.20514/2226-6704-2020-10-6-430-457
9. Nasonova S.N., Zhirov I.V., Magomedov M.M., Saidova M.A., Osmolovskaya Yu.F., Tereschenko S.N. Experience with tafamidis in a patient with transthyretin amyloidosis. Kardiologiia. 2020;60(3):155-160. (In Russ.) DOI: 10.18087/cardio.2020.3.n824
10.
Review
For citations:
Khailo N.V., Belovolova E.V., Tseluiko O.V., Kalmykova D.A., Morozova L.V. Transteritin amyloid cardiomyopathy: a difficult patient for an internist. South Russian Journal of Therapeutic Practice. 2024;5(4):111-118. (In Russ.) https://doi.org/10.21886/2712-8156-2024-5-4-111-118
Views:
434
Email this article 